TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Prostatype Genomics AB
Closing information (x1000 EUR)
| Closing information | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Turnover |
122
|
61
|
1 |
| Financial expenses |
198
|
36
|
8 |
| Earnings before taxes |
-3,734
|
-2,614
|
-1,528 |
| EBITDA |
-3,368
|
-2,407
|
-1,512 |
| Total assets |
4,436
|
2,781
|
3,931 |
| Current assets |
2,335
|
1,273
|
2,111 |
| Current liabilities |
2,206
|
389
|
335 |
| Equity capital |
2,224
|
2,350
|
3,511 |
| - share capital |
646
|
123
|
88 |
| Employees (average) |
7
|
6
|
5 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Solvency |
50.1%
|
84.5%
|
89.3% |
| Turnover per employee |
17
|
10
|
0 |
| Profit as a percentage of turnover |
-3060.7%
|
-4285.2%
|
-152800% |
| Return on assets (ROA) |
-79.7%
|
-92.7%
|
-38.7% |
| Current ratio |
105.8%
|
327.2%
|
630.1% |
| Return on equity (ROE) |
-167.9%
|
-111.2%
|
-43.5% |
| Change turnover | |||
| Change turnover % |
6730%
|
-99% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
20%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.